SAL0132 / Shenzhen Salubris - LARVOL DELTA

SUSTAINED REDUCTIONS IN ANGIOTENSINOGEN AND BLOOD PRESSURE WITH AN RNA INTERFERENCE THERAPEUTIC: INTERIM RESULTS FROM A FIRST-IN-HUMAN PHASE 1 STUDY OF GW906 IN CHINA (ACC 2026) - "A single dose of GW906 produced profound and sustained reductions in serum AGT and BP without hypotension or serious adverse events."

First-in-human • P1 data • Cardiovascular • Hypertension • Hypotension